BioRad Laboratories (BIO.B)
(Delayed Data from NYSE)
$326.78 USD
0.00 (0.00%)
Updated Aug 2, 2024 11:42 AM ET
After-Market: $327.95 +1.17 (0.36%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BIO.B 326.78 0.00(0.00%)
Will BIO.B be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BIO.B based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for BIO.B
Bio-Rad?s Management to Participate in Fireside Chat During Wells Fargo?s 2024 Healthcare Conference
Bio-Rad Appoints Jon DiVincenzo President, Chief Operating Officer
Bio-Rad Laboratories appoints DiVincenzo as COO
Bio-Rad Reports Second-Quarter 2024 Financial Results
Bio-Rad Laboratories, Inc. (BIO) Q2 2024 Earnings Call Transcript